Our Insights

Hormone replacement therapy prescriptions for women aged 50–65 have increased 86% since 2021. The FDA removed boxed warnings on HRT products last year, citing evolving evidence on safety and newer delivery methods. Menopause awareness has gone mainstream, driven by high-profile advocacy, media coverage, and a generation of women demanding better care. By every measure, 2026 should be the best year in decades for women’s access to hormone therapy.

Instead, prescribers are fielding calls from patients who can’t fill their estradiol patch prescriptions.

The estrogen transdermal patch shortage—driven by a convergence of surging demand, limited manufacturers, tariff pressures on overseas production, and the ripple effects of Bayer’s 2023 discontinuation of its Climara patch—has created a real-time access crisis for women on stable HRT regimens. Major pharmacy chains are reporting delays. Patients are scrambling between pharmacies. Prescribers are rewriting prescriptions for alternative formulations mid-cycle.

This moment is forcing a broader conversation about women’s HRT access—one that every prescriber should be part of. Here’s what’s happening, what your options are, and where compounding pharmacy fits into the picture.

What’s Driving the Estrogen Patch Shortage

The shortage isn’t a single-cause problem. It’s the predictable result of demand growth colliding with supply fragility.

Demand surge. The FDA’s removal of boxed warnings on HRT products was a watershed moment. For two decades after the 2002 Women’s Health Initiative, prescribers were cautious about HRT—and many avoided prescribing it altogether. The warning removal, combined with updated clinical guidelines and growing patient demand, triggered a prescribing surge that the supply chain was not built to absorb. HRT prescriptions for women are up 86% since 2021, according to Epic Research data, and the growth shows no sign of slowing.

Manufacturer consolidation. After Bayer discontinued its Climara estradiol patch in late 2023, the U.S. transdermal estrogen market consolidated around just three primary manufacturers: Sandoz, Viatris (formerly Mylan), and Amneal. When demand spikes against a concentrated supply base, shortages propagate faster and resolve more slowly. There simply aren’t enough production lines to flex capacity quickly.

Tariff and supply chain pressure. Tariffs on overseas pharmaceutical manufacturing have added cost and complexity to the transdermal patch supply chain, with several estradiol patch components sourced internationally. These pressures compound (no pun intended) the demand-supply imbalance and make the shortage timeline less predictable.

The clinical preference for transdermal delivery. Transdermal estradiol carries a lower risk of blood clots compared to oral formulations because it bypasses first-pass hepatic metabolism. This safety advantage has made patches the preferred delivery method for many prescribers—which means the shortage is hitting the formulation that clinicians most want to prescribe.

The Menopause Care Gap: A Shortage on Top of a Shortage

The estrogen patch shortage is making headlines, but it’s layered on top of a deeper structural problem: the menopause care gap itself.

The prescriber shortage is real. Data from over 5,400 women treated between 2016 and 2023 shows that only 17% of women seeking menopause-related care received prescription treatment for their symptoms—with dramatic variability across provider specialties. Many primary care physicians, internists, and family medicine providers received minimal menopause training during residency. The result is that millions of symptomatic women either don’t receive treatment, receive suboptimal treatment, or face long wait times to see a menopause-trained specialist.

Access is unevenly distributed. Women in rural areas, women without specialist access, and women whose prescribers are not comfortable initiating HRT face disproportionate barriers. When you add a supply shortage on top of a prescriber shortage, the access gap widens further—and the patients who were already underserved bear the greatest burden.

The conversation is changing. The positive trend in all of this is awareness. Menopause advocacy organizations, celebrity voices, and legislative action (including state-level menopause workplace accommodation bills) have pushed women’s midlife health into the mainstream. More women are asking for HRT. More prescribers are willing to prescribe it. The infrastructure to deliver it—supply chain, trained providers, accessible pharmacy options—is what needs to catch up.

Where Compounded HRT Fits—and Where It Doesn’t

Compounded hormone therapy is not a blanket replacement for FDA-approved products. That distinction matters, and prescribers should be clear-eyed about it.

FDA-approved HRT products should remain the first-line option when they are available and meet the patient’s clinical needs. Dozens of FDA-approved estrogen, progesterone, and combination products exist in various strengths and delivery systems. These products have undergone rigorous review for safety, efficacy, and manufacturing consistency. Both ACOG and the Endocrine Society recommend FDA-approved formulations as the starting point for menopausal hormone therapy.

Compounded HRT becomes clinically relevant in specific circumstances:

When FDA-approved products are unavailable. The current estrogen patch shortage is a concrete example. When a patient on a stable transdermal estradiol regimen cannot fill her prescription because patches are on backorder, the prescriber faces a clinical decision: switch to an oral formulation (with a different risk profile), switch to a different delivery system the patient hasn’t used before, or consider a compounded transdermal estradiol preparation that delivers the same active ingredient through the same route. The last option maintains therapeutic continuity when the commercial product is temporarily inaccessible.

When the patient needs a non-standard strength or dosage form. FDA-approved products come in fixed doses. Some women require titration to a strength between available options—particularly during the initiation phase or when fine-tuning a regimen for symptom control with minimal side effects. Others need a dosage form that isn’t commercially available: a specific cream concentration, a sublingual troche, or a combination preparation that simplifies a multi-product regimen.

When the patient has allergies or sensitivities to inactive ingredients. Patch adhesives, preservatives, dyes, and fillers in commercial products can cause contact dermatitis or other reactions. Compounding allows the active hormone to be delivered in a vehicle free of the specific allergen—a meaningful clinical consideration for women who react to patch adhesives, which is not uncommon.

When combination therapy is appropriate. Some prescribers prefer to combine estrogen and progesterone—or estrogen with testosterone or DHEA—in a single preparation. While the evidence base for specific multi-hormone compounded combinations is more limited than for individual FDA-approved products, combination compounding is widely used in clinical practice to simplify patient regimens and improve adherence.

The Quality Caveat: Why Pharmacy Selection Is the Clinical Decision

Critics of compounded HRT raise a legitimate concern: quality variability. The National Academies documented potency deviations in compounded hormone preparations as high as 26% from labeled amounts. For hormone therapy—where precise dosing directly affects symptom control, endometrial safety, and cardiovascular risk profile—that variability matters.

But the answer to quality variability is not to deny patients access to compounded hormones when they have a legitimate clinical need. The answer is to send those prescriptions to pharmacies that can document their quality.

PCAB-accredited compounding pharmacies represent approximately 8% of U.S. pharmacies. They undergo on-site inspections, demonstrate compliance with USP ⟨795⟩ and ⟨797⟩ compounding standards, verify ingredient sourcing from FDA-registered suppliers, maintain documented potency testing protocols, and ensure staff competency through ongoing assessment programs. For prescribers who compound HRT, the quality conversation is really a pharmacy selection conversation—and accreditation is the clearest available quality signal.

eNavvi’s network requires PCAB or equivalent accreditation from every pharmacy partner. The strategic alliance with ACHC (announced February 2026) provides member pharmacies with a direct accreditation pathway, including a $1,000 discount on PCAB fees. When a prescriber writes a compounded HRT order through eNavvi, the pharmacy on the other end has met a quality threshold that 92% of U.S. pharmacies have not.

What Prescribers Should Do Right Now

Communicate proactively with patients on estrogen patches. If your patients are on transdermal estradiol, don’t wait for them to call you when the pharmacy can’t fill. Reach out now with a plan: confirm their current prescription status, discuss alternative formulations (gels, creams, oral options), and establish a compounding pharmacy relationship as a backup if their preferred product remains unavailable.

Know the full HRT formulation landscape. The estrogen delivery options go well beyond patches and pills. Transdermal gels and creams (both FDA-approved and compounded), vaginal preparations for genitourinary symptoms, sublingual troches, and injectable estradiol are all available. Compounding pharmacies expand this further with Bi-Est formulations (estriol and estradiol combinations), customizable progesterone preparations, and testosterone or DHEA additions when clinically indicated. Prescribers who understand the full toolkit can pivot quickly when one product becomes unavailable.

Establish your compounding partner before you need one. The worst time to vet a compounding pharmacy is when your patient is mid-shortage and needs a prescription filled tomorrow. Identify a PCAB-accredited pharmacy now—verify their HRT compounding volume, confirm potency testing protocols, and set up your prescribing workflow. Digital platforms like eNavvi make this particularly efficient: browse HRT formulation templates, compare pricing across pharmacies, and send electronic prescriptions without phone calls or faxes.

Counsel patients on the difference between compounding and unregulated products. Shortages drive patients to search for alternatives on their own—including online hormone products, over-the-counter "bioidentical" creams, and unverified supplements. Prescribers have an obligation to explain that physician-prescribed, pharmacy-compounded HRT from an accredited pharmacy is fundamentally different from self-directed purchases of unregulated products. The compounding pathway preserves clinical oversight. The internet pathway does not.

Give Your Patients HRT Options—Even During Shortages

Browse eNavvi’s compounded HRT templates—Bi-Est creams, micronized progesterone, testosterone, and DHEA—with transparent cash pricing across PCAB-accredited pharmacies. Free for prescribers. Your patients shouldn’t have to wait for a supply chain to catch up.

Frequently Asked Questions

Q: Why are estrogen patches in short supply in 2026?

A: The estrogen transdermal patch shortage is driven by a combination of surging demand (HRT prescriptions for women are up 86% since 2021), manufacturer consolidation (only three companies produce the majority of U.S. estradiol patches after Bayer discontinued Climara in 2023), the FDA’s removal of boxed warnings on HRT products (which accelerated prescribing), and tariff pressures on overseas pharmaceutical manufacturing. The shortage is affecting major pharmacy chains nationally.

Q: Is compounded estrogen safe?

A: Compounded estrogen preparations use the same bioidentical hormones (estradiol, estriol) found in FDA-approved products, but they are custom-prepared by compounding pharmacies and are not FDA-approved. Quality can vary between pharmacies, which is why pharmacy selection matters. PCAB-accredited compounding pharmacies are held to rigorous standards for potency testing, ingredient sourcing, and compounding consistency. Prescribers should use compounded HRT when FDA-approved products are unavailable or clinically insufficient, and should always route orders to accredited pharmacies.

Q: What alternatives exist if my patient can’t get estradiol patches?

A: Alternatives to estradiol patches include FDA-approved transdermal gels and sprays, oral estradiol (with a different clot-risk profile), vaginal estrogen preparations for genitourinary symptoms, and compounded transdermal estradiol creams from PCAB-accredited pharmacies. Compounded options offer the advantage of customizable dosing and the same transdermal delivery route as patches, maintaining therapeutic continuity for patients who prefer to avoid oral formulations. Prescribers can compare options and pricing on platforms like eNavvi.

As thousands of dermatologists, residents, and prescribers gather in Denver for the American Academy of Dermatology’s 2026 Annual Meeting, the scientific sessions will cover the usual spectrum: biologics for atopic dermatitis, checkpoint inhibitor dermatology, advances in melanoma imaging, new approaches to acne scarring. What won’t get its own plenary session—but will be discussed in hallways, exhibit halls, and dinners across the city—is the rapidly evolving role of compounding in dermatology practice.

Three developments are converging to make 2026 a pivotal year for dermatology compounding: the FDA’s peptide reclassification is restoring access to key molecules used in skin and wound healing, tightening quality standards are separating accredited pharmacies from the rest, and digital prescribing platforms are finally eliminating the operational friction that has kept many dermatologists from incorporating compounding into their standard workflow.

Whether you’re already prescribing compounded topicals or considering it for the first time, here’s what’s shaping dermatology compounding right now—and what to bring back to your practice after AAD.

The Peptide Reclassification: What It Means for Dermatology

The biggest regulatory shift affecting dermatology compounding in 2026 isn’t about topical steroids or retinoids—it’s about peptides. On February 27, HHS announced that approximately 14 of the 19 peptides placed on the FDA’s Category 2 restricted list in late 2023 are expected to be moved back to Category 1, restoring legal access through licensed compounding pharmacies.

Two of those peptides are directly relevant to dermatology practice.

GHK-Cu (copper peptide). GHK-Cu is one of the most studied peptides in skin biology. It occurs naturally in human plasma and declines with age. Research has investigated its role in skin remodeling, collagen synthesis, wound healing, and antioxidant enzyme activity. Before the Category 2 restriction, GHK-Cu was a staple in compounded anti-aging and post-procedure formulations—used topically in serums and creams for photoaging, surgical wound recovery, and overall skin rejuvenation. Its expected return to Category 1 reopens a formulation pathway that dermatology compounders have been unable to offer for over two years.

KPV. Derived from alpha-melanocyte-stimulating hormone (alpha-MSH), KPV has been studied for anti-inflammatory properties relevant to both dermatology and gastroenterology. In skin applications, KPV’s anti-inflammatory mechanism has been explored for conditions involving cutaneous inflammation. While the evidence base remains early-stage, the peptide’s reclassification gives dermatology prescribers an additional compounding option for patients with inflammatory skin conditions that have been inadequately controlled by conventional therapies.

BPC-157. Although primarily associated with musculoskeletal repair, BPC-157’s wound-healing properties have dermatology relevance. Research has investigated its effects on tissue repair, angiogenesis, and collagen formation—mechanisms that intersect with wound care, post-surgical healing, and chronic skin ulcer management. Its expected reclassification may expand the compounding toolkit for prescribers who manage complex wound care cases.

The critical caveat: the formal FDA reclassification has been announced but not yet published in the Federal Register as of mid-March 2026. Until it’s official, these peptides cannot be legally compounded. Prescribers should monitor the FDA’s bulk drug substances list for the formal update before ordering.

Compounded Formulations Gaining Traction in Dermatology

Beyond peptides, several categories of compounded dermatology formulations are seeing increased prescriber interest heading into AAD 2026. These reflect both clinical demand and the limitations of what commercial products currently offer.

High-concentration minoxidil combinations for alopecia. Commercial minoxidil tops out at 5% (topical) and 2% (for women). Compounding pharmacies can prepare minoxidil at concentrations up to 12.5%, and—critically—combine it with topical finasteride (0.1–0.25%) and latanoprost (0.005%) in a single scalp solution. This multi-agent approach, increasingly supported by dermatology literature, is only possible through compounding. For prescribers who treat androgenetic alopecia aggressively, this remains one of the strongest clinical cases for compounding in dermatology.

Customized melasma protocols. The modified Kligman’s formula—combining hydroquinone, tretinoin, and a corticosteroid—has been a dermatology compounding staple for decades. But the compounding advantage goes beyond the standard formula. Prescribers can adjust hydroquinone beyond the commercial 4% ceiling (up to 8% for refractory cases), swap the steroid component based on patient sensitivity, add tranexamic acid or cysteamine for resistant pigmentation, and choose vehicle bases optimized for different skin types and climates. With melasma management increasingly moving toward individualized protocols, compounding gives prescribers the formulation flexibility that fixed commercial products cannot.

Combination acne formulations. Commercial acne products offer two or three fixed-dose combinations. Compounding opens the full matrix: tretinoin at any strength (0.025–0.1%) paired with clindamycin, niacinamide (4–5% for barrier support), azelaic acid, or dapsone—in a vehicle selected for the patient’s skin type. For adult acne patients who have cycled through commercial options, or patients with sensitivities to commercial vehicle ingredients, compounded formulations provide a next step that doesn’t require jumping to systemic therapy.

Post-procedure and wound healing compounds. The post-procedure recovery market is growing alongside the expansion of in-office aesthetic procedures. Compounded preparations combining antimicrobial agents, anti-inflammatory ingredients, and healing promoters—tailored to the specific procedure (chemical peel, laser resurfacing, microneedling, excisional surgery)—allow prescribers to optimize wound healing rather than relying on generic over-the-counter recovery products. The potential return of GHK-Cu to compounding adds another evidence-backed ingredient to this formulation category.

The Quality Question: Why Accreditation Matters for Dermatology Compounds

If there’s one topic that should concern every dermatologist who prescribes compounded medications, it’s potency consistency. The National Academies of Sciences, Engineering, and Medicine documented potency deviations in compounded hormone preparations as high as 26% from the labeled amount. For dermatology compounds, the stakes are similar: a hydroquinone cream compounded at 6% that actually contains 4.2% will deliver a meaningfully different clinical result. A tretinoin preparation with inconsistent distribution in the cream base will produce uneven results across the application area.

This is why pharmacy accreditation matters more in dermatology compounding than many prescribers realize. PCAB-accredited pharmacies—only about 8% of U.S. pharmacies hold this designation—are held to documented standards for potency testing, ingredient sourcing from FDA-registered suppliers, staff competency, and compliance with USP ⟨795⟩ (non-sterile) and ⟨797⟩ (sterile) compounding standards. For prescribers writing complex multi-ingredient topical formulations, the difference between an accredited pharmacy and a non-accredited one is the difference between a verified formulation and a best guess.

The February 2026 strategic alliance between eNavvi and ACHC (the Accreditation Commission for Health Care, which administers PCAB accreditation) was designed specifically to address this quality gap. Every compounding pharmacy in eNavvi’s network holds PCAB or equivalent accreditation, and the ACHC alliance provides member pharmacies with a direct pathway to achieve and maintain that accreditation—including reduced accreditation fees and access to ACHC’s educational resources.

The Digital Prescribing Shift: Why Workflow Matters as Much as Formulation

Ask any dermatologist why they don’t prescribe compounded medications more often, and the answer is rarely clinical. It’s operational. Calling a compounding pharmacy to discuss formulation details. Faxing a handwritten order. Not knowing the price until the patient is called by the pharmacy. Maintaining separate accounts with different pharmacies. The friction isn’t in the medicine—it’s in the workflow.

Digital prescribing platforms designed for compounding are eliminating these barriers. eNavvi’s platform gives dermatology prescribers access to pre-formulated templates for the most commonly prescribed compounds—melasma combinations, alopecia formulations, anti-aging preparations, wound care compounds—that can be customized within the digital workflow. Adjust concentrations, change the vehicle base, add or remove ingredients, and see real-time cash pricing from multiple PCAB-accredited pharmacies side by side before sending the prescription electronically.

For a dermatology practice that currently prescribes even a handful of compounded medications per week, replacing phone calls and faxes with a single digital interface reclaims meaningful clinical time. For practices that have avoided compounding because of the operational overhead, the barrier to entry has never been lower.

What to Bring Back from Denver

AAD 2026 will deliver cutting-edge science across every dermatology subspecialty. But some of the most practical takeaways won’t come from the podium. They’ll come from asking the right questions in the exhibit hall, connecting with compounding pharmacy partners, and returning to practice with a plan to integrate compounding into your clinical workflow more effectively.

Three action items to consider:

Identify your top 3–5 formulations. Look at your prescribing patterns and identify the clinical scenarios where commercial products fall short—whether it’s a melasma patient who has failed standard Kligman’s, an alopecia patient who would benefit from combination minoxidil-finasteride, or a post-procedure protocol you’d like to standardize. Start with these formulations rather than trying to build a comprehensive compounding program overnight.

Vet your compounding partner now. Before you return from Denver, decide which compounding pharmacy you’ll work with. Check for PCAB accreditation, ask about dermatology-specific compounding volume and experience, verify ingredient sourcing, and confirm potency testing protocols. A digital prescribing platform like eNavvi simplifies this: every pharmacy in the network is already accredited and vetted.

Watch the peptide timeline. The formal FDA reclassification of GHK-Cu, KPV, and other dermatology-relevant peptides hasn’t been published yet. When it is, having an accredited compounding partner already in place means you can begin incorporating these peptides into your practice immediately—rather than scrambling to find a pharmacy after the fact.

At AAD? Start Your Compounding Workflow Before You Leave Denver

Explore eNavvi’s dermatology compound templates—melasma, alopecia, acne, wound care, anti-aging—with transparent cash pricing across PCAB-accredited pharmacies. Free for prescribers. No phone calls, no faxes, no separate pharmacy portals.

Frequently Asked Questions

Q: What compounded medications are most commonly prescribed in dermatology?

A: The most commonly compounded dermatology medications include custom-strength hydroquinone and modified Kligman’s formulas for melasma and hyperpigmentation, high-concentration minoxidil (5–12.5%) combined with topical finasteride for alopecia, retinoid-antibiotic combinations for acne, steroid-keratolytic combinations for psoriasis and eczema, and multi-agent wound care and post-procedure preparations. Compounding allows prescribers to customize concentrations, combine multiple active ingredients, and select vehicle bases tailored to each patient’s skin type and condition.

Q: Are GHK-Cu and other peptides available for dermatology compounding in 2026?

A: As of March 2026, GHK-Cu and other peptides previously on the FDA’s Category 2 restricted list are expected to be reclassified to Category 1, which would restore legal access through licensed compounding pharmacies. The HHS announcement was made on February 27, 2026, but the formal reclassification has not yet been published in the Federal Register. Until the official update, these peptides cannot be legally compounded. Prescribers should monitor the FDA’s bulk drug substances list for the formal rule publication.

Q: How do I start prescribing compounded dermatology formulations?

A: Start by identifying the clinical scenarios in your practice where commercial products fall short. Select a PCAB-accredited compounding pharmacy (only ~8% of U.S. pharmacies hold this accreditation) or use a digital prescribing platform like eNavvi that connects prescribers exclusively to accredited pharmacies. You can browse pre-formulated dermatology templates, customize formulations, compare transparent cash pricing, and send prescriptions electronically—eliminating the phone calls and faxes that have historically made compounding operationally difficult for dermatology practices.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA’s Category 2 restricted list are expected to be moved back to Category 1—restoring legal access through licensed compounding pharmacies under a physician’s prescription.

For prescribers who incorporate peptide therapy into their clinical practice—across specialties from regenerative medicine and integrative health to endocrinology and sports medicine—this is the most consequential regulatory development in peptide compounding since the original restrictions were imposed in late 2023. But the announcement comes with critical nuances that every prescriber needs to understand before writing a single order.

What Happened: The Category 2 Restriction and Its Impact

In late 2023, the FDA placed 19 widely used peptides on its Category 2 bulk drug substances list. Category 2 designation means the FDA identified these substances as presenting potential safety concerns and deemed them not currently eligible for routine compounding under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

The practical effect was immediate and sweeping. Licensed compounding pharmacies that had been preparing these peptides for years—under physician prescriptions, with quality controls and potency testing—were required to stop. The 19 restricted peptides spanned nearly every major clinical category in peptide therapy: tissue repair (BPC-157, Thymosin Beta-4), immune modulation (Thymosin Alpha-1, Selank), growth hormone signaling (CJC-1295, Ipamorelin, GHRP-2, GHRP-6), metabolic support (AOD-9604, MOTS-C), cognitive health (Semax, Selank), wound healing (GHK-Cu), and others including KPV, Kisspeptin-10, Melanotan II, PEG-MGF, Epitalon, Cathelicidin LL-37, and Emideltide (DSIP).

For prescribers, the restriction created an immediate clinical gap. Patients who had been on stable, physician-supervised peptide regimens lost access to compounds that had no FDA-approved equivalent. The restrictions also pushed some patients toward unregulated sources—research-grade peptides, overseas suppliers, and gray-market vendors—creating precisely the safety concerns the FDA’s action was intended to prevent.

What’s Changing: The Reclassification to Category 1

The HHS announcement signals that approximately 14 of the 19 restricted peptides will be reclassified from Category 2 to Category 1. Category 1 status means these substances are eligible for compounding by licensed pharmacies under a valid physician prescription—the same regulatory framework that governs compounded HRT, dermatology preparations, and other compounded medications.

Peptides that have already been removed from Category 2 and referred to the Pharmacy Compounding Advisory Committee (PCAC) for formal review include CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank. Others with favorable early clinical profiles—including BPC-157, GHK-Cu, KPV, MOTS-C, Semax, and Thymosin Beta-4 fragment—are expected to follow.

Approximately five peptides are expected to remain on Category 2 due to more serious safety concerns or insufficient human evidence. As of this writing, the formal FDA reclassification has been announced but not yet officially published in the Federal Register. Until the FDA formally updates the Category 2 list, the legal status of these peptides for compounding remains technically unchanged.

Critical distinction for prescribers: Category 1 reclassification does not mean FDA approval. These remain off-label therapeutics. There are no FDA-approved peptide drugs for most of the clinical applications prescribers use them for. Reclassification simply restores the legal pathway for licensed compounding pharmacies to prepare them under physician prescription—with all the clinical oversight, dosing responsibility, and monitoring obligations that entails.

What This Means for Prescribers: Peptides by Clinical Category

The peptides expected to return span five broad clinical categories. Here’s what prescribers in each area should know.

Tissue Repair and Musculoskeletal Recovery. BPC-157 and Thymosin Beta-4 (TB-500) are among the most widely prescribed peptides in regenerative and sports medicine. BPC-157 has been studied for gut healing, tendon and ligament repair, and anti-inflammatory effects. Thymosin Beta-4 has been investigated for wound healing and tissue repair. For prescribers in orthopedics, sports medicine, and integrative health, the return of these peptides restores a therapeutic toolkit that has been unavailable for over two years. Clinical oversight remains essential: dosing protocols, treatment duration, and patient monitoring should follow established peptide therapy guidelines.

Immune Modulation. Thymosin Alpha-1 has the strongest clinical evidence base of any peptide on the list, with published research in infectious disease support, immune reconstitution, and oncology-adjacent immune modulation. It was used clinically in over 35 countries before the FDA’s Category 2 restriction. Selank, studied for its anxiolytic and immunomodulatory properties, is also expected to return. For prescribers in functional medicine and immunology, these peptides fill a gap that no FDA-approved product currently addresses.

Growth Hormone Signaling and Metabolic Support. CJC-1295 and Ipamorelin—often prescribed in combination—are growth hormone-releasing peptides used to support sleep quality, lean body composition, metabolic health, and recovery. AOD-9604, a modified fragment of human growth hormone, has been studied for its effects on fat metabolism without the broader growth hormone effects. MOTS-C, a mitochondrial-derived peptide, has been investigated for metabolic regulation and exercise performance. These peptides serve a prescriber population in anti-aging medicine, endocrinology, and metabolic health that had limited alternatives during the restriction period.

Cognitive Health and Neuroprotection. Semax, a synthetic peptide derived from ACTH, has been studied for cognitive enhancement, neuroprotection, and attention support. Selank overlaps here as well, with research into its effects on anxiety and cognitive function. For prescribers in neurology and cognitive health, the reclassification reopens access to peptides that were previously part of established treatment protocols for select patients.

Skin and Wound Healing. GHK-Cu (copper peptide) is one of the most studied peptides for skin remodeling, wound healing, and anti-aging applications. KPV, derived from alpha-melanocyte-stimulating hormone, has been studied for its anti-inflammatory properties in skin and gut conditions. For prescribers in dermatology and aesthetic medicine, these peptides expand the compounded formulation toolkit alongside established topical compounds.

The Compliance Imperative: Why Pharmacy Selection Matters More Than Ever

The return of compounded peptides to legal status amplifies—rather than diminishes—the importance of pharmacy quality and regulatory compliance. Here’s why.

Sourcing verification is critical. Peptides are complex molecules that require verified sourcing from FDA-registered API suppliers, certificates of analysis for identity and purity, and proper cold-chain handling. During the restriction period, gray-market peptide vendors proliferated—many without any of these safeguards. As peptides return to licensed compounding, prescribers must ensure they’re ordering from pharmacies that can document their entire supply chain, not pharmacies that pivot to peptides opportunistically without the infrastructure to handle them safely.

Potency and sterility testing are non-negotiable. Injectable peptides demand the highest compounding standards: sterile technique, potency verification, endotoxin testing, and stability data. PCAB-accredited pharmacies are held to these standards through documented protocols, on-site inspections, and compliance with USP ⟨797⟩ for sterile compounding. For peptides—where dosing is measured in micrograms and administration is typically subcutaneous injection—compounding quality directly determines clinical safety.

Off-label prescribing requires clinical discipline. Category 1 reclassification does not create an evidence base that didn’t exist before. These peptides remain investigational for most applications. Responsible prescribing means proper patient selection, evidence-informed dosing, baseline and follow-up lab monitoring where appropriate, documented informed consent, and clinical follow-up to assess response. The regulatory landscape is shifting. The need for physician-guided, compliance-first prescribing is not.

Dermatology has one of the strongest clinical cases for compounding. Patients present with conditions that demand specific concentrations, unique ingredient combinations, or vehicles that commercial products simply don’t offer. A patient who needs a higher-strength tretinoin than what’s commercially available. A combination antifungal-steroid-antibiotic in a single topical. A hydroquinone preparation without a specific preservative that triggers contact dermatitis. These are everyday clinical scenarios in dermatology—and compounding addresses them.

Yet many prescribers default to commercial alternatives or avoid compounding entirely because the ordering workflow is cumbersome, quality is uncertain, or they’re unsure what’s available. This guide covers the clinical landscape of compounded dermatology medications—common formulations, quality considerations, and how digital prescribing tools are making dermatology compounding more accessible.

When Compounded Dermatology Formulations Are Clinically Indicated

FDA-approved dermatology products cover a wide therapeutic range, and they should be the starting point when they meet the patient’s needs. Compounding becomes relevant in specific clinical circumstances:

Custom concentration requirements. A patient may need a strength that isn’t commercially available—a higher or lower concentration of a retinoid, a non-standard percentage of hydroquinone, or a steroid potency between two available commercial products. Compounding allows precise strength adjustments.

Multi-agent combination therapy. Dermatology frequently benefits from combining multiple active ingredients into a single preparation. A melasma formulation combining hydroquinone, tretinoin, and a corticosteroid. A wound care compound with an antimicrobial, analgesic, and healing agent. Commercial products rarely offer these combinations, and applying three separate products creates compliance challenges for patients.

Allergen or excipient avoidance. Patients with contact sensitivities to preservatives, fragrances, dyes, or specific vehicle ingredients may react to a commercial product’s inactive ingredients. Compounding allows the active drug to be delivered in a hypoallergenic base free of the offending excipient.

Vehicle optimization. The vehicle matters in dermatology. An ointment base for severely dry plaques, a gel for seborrheic areas, a foam for scalp application, a cream for cosmetically sensitive areas. Compounding lets the prescriber match the vehicle to the body site and skin condition rather than accepting whatever vehicle the manufacturer chose.

Common Compounded Dermatology Formulations

The following formulations represent the most frequently compounded dermatology preparations. Concentrations reflect common prescribing ranges; individual clinical judgment should always guide specific prescribing decisions.

Hyperpigmentation and Melasma. The modified Kligman’s triple combination cream remains one of the most widely prescribed compounded dermatology formulations. A typical preparation combines hydroquinone (4–8%), tretinoin (0.025–0.05%), and fluocinolone acetonide (0.01%) in a single topical cream. Compounding allows prescribers to adjust the hydroquinone concentration beyond the 4% ceiling of most commercial products and to customize the vehicle for patient tolerance.

Acne. Custom retinoid and antibiotic combinations give prescribers flexibility that commercial fixed-dose products cannot match. Common formulations include tretinoin (0.025–0.1%) paired with clindamycin (1%) and niacinamide (4–5%). Compounding allows the prescriber to fine-tune retinoid strength based on patient tolerance and to add agents like niacinamide for barrier support—combinations not available in any single commercial product.

Anti-Aging and Photoaging. High-strength retinoid and antioxidant creams are among the most requested compounded preparations in cosmetic dermatology. Formulations typically feature tretinoin (0.05–0.1%) combined with vitamin C (10–20%) and hyaluronic acid in a cosmetically elegant base. Compounding allows concentrations of vitamin C and retinoid that exceed what’s available in over-the-counter or prescription commercial products.

Fungal Infections. Multi-agent antifungal topicals combine two or more antifungal agents—such as ketoconazole (2%) and clotrimazole (1%)—sometimes with a low-potency corticosteroid to manage inflammation. This approach is particularly useful for refractory dermatophyte infections or mixed fungal-inflammatory presentations where a single commercial antifungal has proven insufficient.

Psoriasis and Eczema. Steroid and keratolytic combinations address both inflammation and hyperkeratosis in a single application. Common formulations pair betamethasone (0.05–0.1%) with salicylic acid (3–6%) and calcipotriene (0.005%). Compounding allows the prescriber to adjust steroid potency by body site—lower for face and flexures, higher for thick plaques on elbows and knees—in a way that fixed commercial products cannot accommodate.

Wound Care. Antimicrobial and healing agent preparations combine ingredients like mupirocin (2%) with agents that promote tissue repair—misoprostol, phenytoin, or nifedipine—tailored to the wound type and healing stage. These multi-agent compounds are used in chronic wound management, post-surgical care, and pressure injury treatment where commercial wound care products offer insufficient therapeutic breadth.

Scar Management. Silicone-based preparations with active ingredients offer a compounded alternative to commercial scar sheets and gels. Formulations may combine a silicone base with vitamin E, onion extract, and a low-potency corticosteroid. Compounding allows the prescriber to adjust the active ingredient profile based on scar type (hypertrophic, keloid, post-surgical) and patient response.

Alopecia. Scalp-targeted formulations represent a growing area of compounding interest. Common preparations include minoxidil at higher concentrations than commercially available (5–12.5%), often combined with topical finasteride (0.1–0.25%) and latanoprost (0.005%) in a single scalp solution. Compounding is the only way to deliver these multi-agent combinations in a single application.

Nail Conditions. Nail-penetrating antifungal formulations use specialized vehicles—often DMSO-based—to deliver antifungal agents like ciclopirox and terbinafine through the nail plate. Onychomycosis is notoriously difficult to treat topically with commercial products; compounded formulations with enhanced penetration vehicles offer an alternative for patients who cannot tolerate or prefer to avoid systemic antifungals.

Note: Compounded preparations are not FDA-approved. Prescribers should document the clinical rationale for compounding, explain to patients that the formulation is custom-prepared, and select accredited compounding pharmacies to minimize quality variability.

Quality Matters More in Dermatology Than You Think

Topical compounding quality directly affects therapeutic outcomes. Potency accuracy determines whether the active ingredient is delivered at the intended concentration. Vehicle stability determines whether the active remains evenly distributed and bioavailable throughout the preparation’s shelf life. Beyond-use dating (BUD) determines how long the compound remains clinically effective.

Studies have documented significant potency variability in compounded preparations across pharmacies. For topical dermatology compounds—where a 4% hydroquinone cream that tests at 2.8% delivers a meaningfully different clinical effect—this variability has real patient-care implications.

PCAB-accredited pharmacies are held to rigorous standards for compounding consistency, potency verification, and ingredient sourcing from FDA-registered suppliers. For dermatology prescribers who send compound orders regularly, routing those orders exclusively to accredited pharmacies is the simplest way to control for quality variability.

How to Order Compounded Dermatology Medications Digitally

Historically, prescribing a compounded dermatological preparation meant calling a specific pharmacy, discussing the formulation details, and faxing a written order. Digital prescribing platforms designed for compounding eliminate this friction.

eNavvi’s platform provides access to pre-formulated dermatology templates for the most commonly prescribed compounds—including melasma combinations, high-strength retinoids, and custom alopecia formulations. Each template is fully customizable: adjust concentrations, change the vehicle base, add or remove ingredients, and modify quantities within the digital workflow. Real-time cash pricing from multiple PCAB-accredited pharmacies is displayed side by side, so prescribers can compare costs before finalizing the order.

For dermatology practices that prescribe compounds regularly, this workflow replaces dozens of phone calls and faxes per week with a single digital interface—complete with audit trails, HIPAA-secure transmission, and documented formulation records for each patient.

Browse Dermatology Compound Templates

Explore eNavvi’s pre-formulated dermatology compounds—melasma, acne, alopecia, wound care, and more—with transparent cash pricing across PCAB-accredited pharmacies.

Get Started Free at eNavvi.com →

Frequently Asked Questions

Q: What dermatology medications can be compounded?

A: Nearly any topical dermatology medication can be compounded, including retinoids (tretinoin), hydroquinone, antifungals (ketoconazole, terbinafine), corticosteroids, antibiotics (clindamycin, mupirocin), minoxidil for alopecia, and multi-agent combinations. Compounding allows custom concentrations, allergen-free bases, and combination formulations that are not commercially available.

Q: Are compounded dermatology medications covered by insurance?

A: Most compounded dermatology medications are cash-pay and are not covered by insurance. Because they are custom-prepared without FDA approval, insurance plans and PBMs typically do not adjudicate claims for compounded topicals. This makes transparent cash pricing especially important—platforms like eNavvi display real-time prices from multiple pharmacies so prescribers and patients can compare costs before the order is placed.

Q: How do I choose a compounding pharmacy for dermatology prescriptions?

A: Look for PCAB accreditation (only ~8% of U.S. pharmacies hold this), verify they compound dermatology formulations regularly (volume indicates process consistency), confirm ingredient sourcing from FDA-registered suppliers, and ask about potency testing protocols. Digital prescribing platforms like eNavvi include only accredited pharmacies in their network, simplifying the selection process.

Hormone replacement therapy compounding represents the single largest category in compounding pharmacy, accounting for approximately 36% of all compounding prescriptions nationally according to the Alliance for Pharmacy Compounding. For prescribers in family medicine, OB/GYN, endocrinology, and integrative medicine, compounded HRT fills a specific clinical need: providing hormone preparations in formulations, dosage forms, and strengths that FDA-approved products do not cover.

This guide walks through the clinical landscape of compounded HRT prescribing—from when compounding is clinically appropriate, to the formulations and dosage forms available, to how prescribers can select quality compounding partners and streamline the ordering process.

When Compounded HRT Is Clinically Appropriate

FDA-approved hormone therapy products should be the starting point for most patients. Dozens of FDA-approved estrogen, progesterone, and testosterone products are available in various strengths and delivery systems, and these products have undergone rigorous review for safety, efficacy, and manufacturing consistency. Both ACOG and the Endocrine Society recommend FDA-approved formulations as first-line therapy when they meet the patient’s clinical needs.

Compounded HRT becomes clinically relevant when FDA-approved options are insufficient for a specific patient’s situation. Common clinical scenarios include:

Allergy or sensitivity to inactive ingredients. A patient may react to a dye, preservative, filler, or adhesive in a commercial product. Compounding allows the formulation to exclude the specific allergen while delivering the same active ingredient.

Need for a non-standard strength. FDA-approved products come in fixed doses. Some patients require titration to a strength between commercially available options, or need a starting dose lower than the lowest commercial product offers. Compounding allows precise dose customization.

Preferred dosage form not commercially available. A patient may need a topical cream when only oral capsules are available in the needed hormone, or a sublingual preparation when they cannot tolerate oral delivery. Compounding expands the dosage-form options beyond what the commercial market provides.

Combination therapy in a single preparation. Some prescribers prefer to combine multiple hormones (e.g., estriol and estradiol, or estrogen with progesterone) into a single preparation to simplify the patient’s regimen. While evidence supporting specific multi-hormone combinations is limited, this approach is widely used in clinical practice when single-agent commercial products would require the patient to use multiple separate products.

Important clinical note: Prescribers should counsel patients that compounded preparations are not FDA-approved, that quality can vary between pharmacies, and that the evidence base for specific compounded formulations is more limited than for FDA-approved products. These are essential elements of informed consent when prescribing compounded HRT.

Executive summary

Compounded medications continue to play an important role in patient care when FDA-approved products are unavailable, contraindicated, or insufficient for individualized needs. Yet variability in quality, oversight, and pricing creates risk for both patients and physicians. In 2025, digital prescribing platforms offer new opportunities for safer, compliant, and transparent access to compounded therapies.

1) What counts as compounding in 2025?

Compounding is defined as the preparation of a medication to meet the unique needs of a patient that cannot be met with an FDA-approved drug. This occurs under two main pathways: 503A traditional compounding pharmacies, which produce patient-specific prescriptions, and 503B outsourcing facilities, which compound in bulk under cGMP standards.

2) Why physicians prescribe compounded drugs

• Patient-specific formulations: Alternative strengths, routes (e.g., rectal suppositories for GI indications), or dosage forms.
• Allergy avoidance: Removal of excipients, dyes, or allergens.
• Therapy gaps: When FDA-approved options are unavailable or discontinued.
• Shortage mitigation: Temporarily filling access gaps.

3) Compliance & liability considerations

Physicians should prescribe only through accredited, reputable pharmacies. PCAB accreditation signals adherence to USP standards. Documentation of medical necessity is recommended, and physicians should avoid writing for compounded versions of drugs with readily available FDA-approved alternatives unless justified.

4) Cost transparency & patient trust

Pricing for compounded medications is notoriously opaque and varies widely by pharmacy. Digital platforms that show comparative pricing at the point of prescribing reduce sticker shock, increase adherence, and enhance patient trust. eNavvi, for example, integrates a compounding network that allows physicians to compare cash prices across PCAB-accredited pharmacies before finalizing the prescription.

5) Case examples

• Dermatology: Customized topical creams (multi-agent formulations not commercially available).
• GI: Rectal mesalamine suppositories for IBD patients intolerant to commercial formulations.
• HRT: Bioidentical hormone replacement, where individualized dosing is required.

6) Streamlined prescribing workflow

Search and select compounded therapy (formulation, dosage form).

Compare accredited pharmacies and cash pricing.

Document indication and rationale (especially when FDA alternatives exist).

Route digitally to the pharmacy, minimizing fax/phone steps.

Track and follow up for adherence, AE reporting, and adjustments.

Key takeaways

• Compounded medications remain clinically essential in select scenarios but pose compliance and liability risks.
• Accreditation and documentation are key to mitigating risk.
• Transparent digital prescribing tools improve trust, adherence, and outcomes.

Unwanted facial hair can be more than a cosmetic nuisance—it can affect confidence, daily routines, and quality of life. Eflornithine HCl 13.9% cream, available for fast digital prescribing through eNavvi, offers a clinically proven, prescription‑strength way to slow hair growth and extend the smooth interval between hair‑removal sessions.

What Is Eflornithine HCl 13.9% Cream?

Eflornithine is a topical medication formulated at 13.9% strength. Unlike depilatories that dissolve hair shafts or lasers that target follicles with heat, eflornithine works inside the follicle to reduce the rate and coarseness of new hair growth—making it an ideal adjunct to shaving, waxing, threading, or laser therapy.

Fast Facts

Attribute

Details

Active ingredient: Eflornithine hydrochloride monohydrate 13.9%

Presentation: 30‑gram tube (≈ 30‑day supply)

Price: $55

Shipping: 2‑day shipping via eNavvi partner pharmacy

Frequency: Apply twice daily, at least 8 hours apart

Onset of benefit: Visible slowing of growth in 4‑8 weeks (max 6 months)

FDA status: Prescription‑only (Rx)

How Does Eflornithine Work?

Mechanism of Action

Hair shafts grow when follicles produce the structural protein keratin, a process that relies on polyamines—small molecules synthesized by the enzyme ornithine decarboxylase (ODC). Topical eflornithine is a selective, irreversible ODC inhibitor:

Blocks polyamine synthesis inside the hair bulb.

Slows keratin assembly and cell division in the follicle matrix.

Extends the anagen (growth) phase, reducing the speed and thickness of emerging hair.

The result is finer, slower‑growing hair that requires less frequent removal. Because eflornithine does not destroy follicles, growth gradually returns to baseline about eight weeks after discontinuation.

Who Benefits Most?

Ideal Candidates

Women bothered by unwanted facial or submental hair (e.g., hirsutism, PCOS)

Patients seeking a non‑laser option for darker skin phototypes

Those using laser/IPL who want to extend treatment intervals

People experiencing irritation from frequent waxing or depilatories

eNavvi Tip: Dermatologists and primary‑care providers can digitally prescribe eflornithine in seconds, and patients receive it at their doorstep within two business days—no in‑person pharmacy trip required.

When Not to Use Eflornithine

• Known hypersensitivity to eflornithine or cream excipients
• Broken, inflamed, or infected skin in the application area
• Children (< 12 years): safety not established
• Pregnancy: Category C—use only if anticipated benefits outweigh potential fetal risk
• Breastfeeding: Insufficient data; exercise caution and avoid application near the nipple area

Always discuss systemic conditions (e.g., severe acne, dermatitis), concurrent topical treatments (retinoids, benzoyl peroxide), and hair‑removal methods with your prescriber.

Dosage & Application Guide

Prep the skin: Remove hair by your usual method (shave, wax, etc.) and wait ≥ 5 min.

Clean & dry: Gently cleanse, pat dry.

Apply a thin film: Use pea‑sized dabs to cover only affected areas (avoid eyes, mouth, mucous membranes). Rub in until absorbed.

Frequency: 2× daily, morning & evening, at least 8 h apart.

Post‑application care: Avoid washing, swimming, or sweating heavily for 4 h after application.

Cosmetics: Makeup or sunscreen may be applied after the cream dries (~ 5 min).

If no clinical improvement is observed after 6 months, reassess therapy.

Expected Timeline

• Weeks 0‑4: Subtle reduction in stubble feel; less five‑o‑clock shadow.
• Weeks 4‑8: Noticeable slowdown in regrowth; hairs appear finer.
• Months 3‑6: Peak effect; many users can shave/wax half as often.
• > 6 months: Continue maintenance if satisfied; discontinue if inadequate response.

Stopping treatment leads to gradual return to baseline hair density within ~ 8 weeks.

Possible Side Effects

Most reactions are mild and limited to the skin surface:

• Transient burning or stinging at application site
• Redness, dryness, or itching
• Acneiform eruptions or folliculitis
• Tingling or rash
• Contact dermatitis (rare)

Management tips: Use a gentle cleanser, avoid alcohol‑based toners, and apply non‑comedogenic moisturizer if needed. Discontinue and consult a clinician if severe irritation or allergic rash develops.

Systemic absorption is < 1%, so systemic side effects are exceedingly rare.

Best‑Practice Tips for Clinicians

• Combine eflornithine with laser or IPL for synergistic results—slowing regrowth lets energy‑based treatments target fewer, slower‑cycling follicles.
• Consider hormonal evaluation (androgen levels, PCOS work‑up) for women with rapid, coarse facial hair.
• Document baseline photography; objective visuals help motivate adherence and gauge progress.
• Remind patients that consistency is key—twice‑daily use is required for optimal suppression.

eNavvi Makes Prescribing Effortless

With eNavvi, you can:

Select Eflornithine HCl 13.9% cream

E‑sign the prescription in < 30 seconds.

Ship—our partner pharmacy delivers the 30‑g tube for $55 (2‑day shipping included).

Patients receive automated refill reminders, and you can track adherence and outcomes in your eNavvi dashboard—streamlining follow‑up care.

Key Takeaways

• Topical eflornithine slows hair growth by inhibiting the ODC enzyme inside follicles.
• Twice‑daily application delivers visible results in 4‑8 weeks; reassess at 6 months.
• Common side effects are mild and local; systemic exposure is minimal.
• Ideal for women with unwanted facial hair and a complement to laser or traditional hair‑removal methods.
• eNavvi enables seamless prescribing and quick shipping, improving treatment initiation and adherence.

Ready to offer your patients a science‑backed solution for smoother skin? Log in to eNavvi, select Eflornithine HCl 13.9% cream, and make unwanted hair one less worry.

Disclaimer

This blog post is for informational purposes only and does not constitute medical advice. Patients should consult a licensed healthcare professional to determine whether eflornithine is appropriate for their individual needs.

In the realm of dermatology and pain management, chronic pruritus remains a challenging symptom, often refractory to standard therapies and significantly impacting patient quality of life. For physicians seeking innovative, patient-specific interventions, compounded topical formulations offer a tailored approach. The amitriptyline HCl/lidocaine HCl/pramoxine HCl 5/5/1% cream represents a multimodal compounded agent designed for localized itch relief, particularly in neuropathic or mixed-etiology pruritus. Available through eNavvi's ePrescribing platform at $35 for a 30-gram tube (30-day supply) with 2-day shipping, this formulation combines sodium channel blockade, local anesthesia, and sensory nerve modulation to address the itch-scratch cycle effectively.

This article explores the pharmacology, evidence-based efficacy, prescribing considerations, and integration into clinical practice for this compounded cream, optimizing for searches related to "compounded topical pruritus treatment," "neuropathic itch management," and "amitriptyline lidocaine pramoxine cream."

Pharmacodynamics and Mechanism of Action

The synergistic components of this cream target peripheral neural pathways implicated in pruritus pathogenesis:

• Amitriptyline HCl (5%): As a tricyclic antidepressant, amitriptyline inhibits voltage-gated sodium channels in peripheral nerves, reducing ectopic firing associated with neuropathic itch. Topical application minimizes systemic anticholinergic effects while providing analgesia comparable to local anesthetics. It is particularly efficacious in conditions involving nerve hypersensitivity, such as postherpetic neuralgia or brachioradial pruritus.
• Lidocaine HCl (5%): A amide local anesthetic that stabilizes neuronal membranes by blocking sodium influx, thereby interrupting itch and pain signal transmission. Its rapid onset (within minutes) makes it ideal for acute symptom control in inflammatory or uremic pruritus.
• Pramoxine HCl (1%): A non-amide anesthetic that desensitizes sensory nerve endings, offering antipruritic effects without the risk of amide cross-reactivity. Clinical data support its use in uremic and elderly pruritus, where it reduces itch intensity more effectively than vehicle controls.

This combination parallels ketamine-amitriptyline-lidocaine (KAL) formulations, which have demonstrated efficacy in chronic pruritus through retrospective analyses, with response rates of 50-70% in refractory cases. By substituting pramoxine for ketamine, this variant may reduce potential irritancy while maintaining multimodal blockade.

Clinical Indications and Evidence

Indicated for chronic pruritus of neuropathic, uremic, or idiopathic origin, this cream is suitable for conditions such as:

• Brachioradial pruritus or prurigo nodularis, where nerve modulation is key.
• Atopic dermatitis flares or psoriasis-associated itch, augmenting anti-inflammatory regimens.
• Cancer-related or CKD-associated pruritus, as adjunctive therapy.

Retrospective studies on analogous compounded topicals (e.g., KAL) report significant itch reduction in 60% of patients with minimal adverse events, primarily transient erythema. Pramoxine-inclusive formulations have shown superior efficacy in hemodialysis patients, underscoring its role in uremic pruritus. While large-scale RCTs are limited for this exact combination, mechanistic overlap with validated agents supports its use in treatment-resistant cases.

Prescribing Guidelines and Safety Profile

Prescribe as a thin layer applied 2-4 times daily to intact skin, avoiding occlusion to prevent enhanced absorption. The 30-gram tube supports a 30-day course for localized areas.

Adverse Effects: Primarily local (e.g., transient stinging in 10-20% of users); systemic risks (e.g., sedation from amitriptyline) are rare with topical use but warrant monitoring in elderly or renally impaired patients.

Contraindications: Hypersensitivity to components; caution with concurrent antiarrhythmics or MAOIs due to potential interactions.

Monitoring: Assess response at 2 weeks; discontinue if irritation persists.

eNavvi facilitates seamless prescribing with real-time pricing transparency ($35/30g, 2-day shipping) and integration with networks like Mark Cuban Cost Plus Drug Company. As a physician-founded platform, it streamlines compounded medication orders, reducing administrative burden.

Integrating into Practice: A Cost-Effective Option

For physicians managing refractory pruritus, this cream offers a low-cost, accessible alternative to systemic therapies, aligning with guidelines emphasizing topical-first approaches. Leverage eNavvi for efficient ePrescribing and patient education on adherence.

In summary, amitriptyline HCl/lidocaine HCl/pramoxine HCl 5/5/1% cream provides a compelling option for pruritus management, backed by mechanistic rationale and supportive evidence from similar formulations. Explore prescribing via eNavvi to enhance patient outcomes.

Disclaimer: This content is for educational purposes and not a substitute for clinical judgment. Consult primary literature and patient-specific factors before prescribing.

Scars are not one-size-fits-all. From hypertrophic nodularity to post-inflammatory hyperpigmentation (PIH) and atrophic collagen loss, their presentations—and responses—vary. While over-the-counter silicone gels help some patients, many require targeted formulations to address pigmentation, erythema, and remodeling more precisely.

Compounded scar treatments from eNavvi offer:

• Precision ingredients adjusted to patient phenotype, Fitzpatrick type, and healing stage
• Silicone-plus vehicles (Pracasil® Plus) to enhance absorption while maintaining a moist, occlusive environment
• Streamlined application through single-tube, multitarget formulations that improve adherence

All preparations are fulfilled by Foothills Professional Pharmacy, PCAB-accredited and licensed in all 50 states, with 2-day nationwide shipping and flat transparent pricing: $55 for a 30g, 30-day supply.

Key Compounded Scar Therapies Available on eNavvi

1. Hydroquinone 6% in Pracasil® Plus Base

This high-potency skin-lightening agent remains the gold standard for post-inflammatory hyperpigmentation. Compounded in a silicone-based gel, it provides dual-action benefit: hydroquinone reduces melanin synthesis via tyrosinase inhibition, while Pracasil® Plus softens and flattens scar tissue.

Clinical Use: Best for mature, pigmented scars—especially in Fitzpatrick III–VI skin after acne surgery, trauma, or lasers.

Prescribing Note: Apply a thin layer twice daily for up to 12 weeks; always pair with SPF 50+.

Caution: Contraindicated in pregnancy and breastfeeding. Limit continuous use to under 6 months to reduce risk of ochronosis.

2. Niacinamide 2% + Tretinoin 0.1% in Pracasil® Plus

This multitarget formula combines anti-inflammatory, barrier-restoring, and collagen-remodeling effects, making it ideal for early hypertrophic or mixed-type scars. Niacinamide reduces cytokine activity and transepidermal water loss, while tretinoin upregulates collagenase activity to encourage smoother remodeling.

Clinical Use: Begin 2 weeks post-procedure once epithelialized. Excellent for early surgical, ablative, or traumatic scars.

Prescribing Note: Apply a pea-sized amount nightly for 12–16 weeks. Titrate to every other night for sensitive skin.

Caution: Mild irritation and photosensitivity are expected—ensure patients use broad-spectrum sun protection.

3. Niacinamide 2% in Pracasil® Plus (Mono‑Active)

A minimalist yet effective option for sensitive skin or post-procedural cases unable to tolerate retinoids or hydroquinone. This formulation strengthens the skin barrier, reduces mast-cell-mediated inflammation, and soothes reactivity—making it suitable for both adult and pediatric patients.

Clinical Use: Ideal for postsurgical scars in pregnancy, pediatric dermatology, or rosacea-prone skin.

Prescribing Note: Apply twice daily for a minimum of 8 weeks. Often used as maintenance after more intensive therapies.

Caution: Safe across all skin types and life stages. No known contraindications.

How to Prescribe Scar Compounds via eNavvi

eNavvi’s workflow is designed for clinical speed and patient clarity:

Log in to your eNavvi account and select “Compounded eRx," then "Scar"

Choose your formulation—default SIG, volume, and quantity are preloaded.

E-sign the order and counsel your patient on application schedule and photoprotection.

Track healing via 4-week photographic intervals and adjust formulation or frequency as needed.

Clinical Data Snapshot

• Pracasil® Plus base (silicone + pracaxi oil) achieved >38% improvement on the Vancouver Scar Scale in a 12-week prospective series.
• Hydroquinone 6% improves PIH by 60–70% within 8–12 weeks in skin-of-color studies.
• Tretinoin 0.1% promotes 21% increase in dermal collagen fiber organization after 6 months (histologically confirmed).
• Niacinamide 2% improves barrier strength and reduces inflammation within 6 weeks in split-scar studies.

Key Takeaways for Dermatology Practices

• Compounded scar gels allow personalized, phenotype-specific interventions across scar types and skin tones.
• The Pracasil® Plus base enhances bioavailability while reducing irritation and occlusion-induced maceration.
• All formulas are affordably priced at $55 and ship nationwide within 48 hours—supporting timely care across geographies.
• This model supports high-acuity procedures, enhances adherence, and integrates seamlessly into post-op protocols.

Understanding Primary Focal Hyperhidrosis

Primary focal hyperhidrosis is a chronic condition affecting approximately 5% of the population, characterized by excessive sweating of the axillae, palms, soles, or face—often beginning in adolescence. The condition results from overactive sympathetic stimulation of eccrine sweat glands, independent of thermoregulatory need.

Before initiating treatment, it’s essential to rule out secondary causes like hyperthyroidism, infections, diabetes, or medication side effects.

First-Line Treatments: Where OTC Antiperspirants Fall Short

Clinical guidelines from the American Academy of Family Physicians (AAFP) and the International Hyperhidrosis Society recommend topical aluminum chloride hexahydrate (15–20%) as a first-line option. This agent works by mechanically obstructing sweat ducts.

However, up to 20% of users experience irritant contact dermatitis, and many with moderate-to-severe hyperhidrosis find it ineffective long-term.

When to Consider Compounded Topical Anticholinergics

For patients who do not respond to or cannot tolerate aluminum salts alone, topical anticholinergic therapy becomes a logical next step. These agents block muscarinic receptors in the skin, reducing sweat production without the systemic side effects of oral anticholinergics.

While commercial products like glycopyrronium wipes are FDA-approved, they are expensive and often limited to single-use formats. Compounded formulations offer:

• Customizable concentrations
• Larger volumes for broader or off-label application
• Lower cost and faster access

How eNavvi’s Compounded Solutions Work

Pharmacy solutions on eNavvi offer two compounded formulations for primary focal hyperhidrosis, prepared by Foothills Professional Pharmacy:

Aluminum Chloride 25% + Glycopyrrolate 0.5% Solution

• Ideal for mild-to-moderate axillary hyperhidrosis
• Dual mechanism: physical ductal blockage and cholinergic inhibition
• Nightly use x2 weeks, then PRN

Glycopyrrolate 1% Spray

• Best suited for moderate-to-severe or multi-site sweating
• Convenient once-daily spray format
• Particularly useful for craniofacial, palmar, or truncal application

These solutions use quick-evaporating, low-residue vehicles that enhance skin penetration and limit messiness—important for daily adherence.

Evidence Supporting Topical Anticholinergics

• 20% aluminum chloride has shown >80% efficacy in reducing axillary sweat levels in randomized trials.
• 1% glycopyrronium cream, in a 518-patient phase 3b study, demonstrated long-term efficacy and QoL improvements over 72 weeks.
• Smaller studies have confirmed that 1–2% glycopyrrolate solutions or sprays are effective for axillary and facial sweating, offering comparable benefits to botulinum toxin with fewer side effects.
• Anticholinergic-related adverse effects are rare, with <5% discontinuation due to mild erythema or dry mouth.

How to Prescribe Through eNavvi

Choose your formula:

• For mild axillary cases: start with Aluminum Chloride 25% + Glycopyrrolate 0.5% at bedtime.
• For multi-site or persistent cases: go with Glycopyrrolate 1% spray once daily.

Send an e-prescription to Foothills Professional Pharmacy – Mail Service

Counsel patients on correct usage:

• Apply to dry skin at night, wash off after 6–8 hours
• Avoid mucous membranes and occlusion
• Use caution in patients with glaucoma, BPH, or myasthenia gravis

Monitor response using the Hyperhidrosis Disease Severity Scale (HDSS) and escalate to systemic or procedural options only if needed.

Key Takeaways

• Topical therapy is the safest first-line option for primary focal hyperhidrosis.
• Combining aluminum chloride with glycopyrrolate provides dual-action efficacy with limited irritation.
• eNavvi’s pharmacy partners offer compounded therapies that costs <$1.50/day
• Evidence supports these concentrations as effective, safe alternatives to systemic medications or invasive interventions.

Early intervention with topical solutions can delay or prevent the need for oral agents, botulinum toxin, or surgical procedures.

Snapshot of the 2024 AAD Update

The newest American Academy of Dermatology (AAD) guideline reiterates three directives physicians already know—but now frames them as strong recommendations:

• Always pair topical or oral antibiotics with benzoyl peroxide to blunt resistance.
• Lean on fixed-dose combinations (antibiotic ± BPO ± retinoid) to simplify regimens and boost adherence.
• Reserve oral antibiotics to ≤4 months and surround them with topical retinoids or BPO for long-term control.

Benzoyl peroxide remains resistance-free after decades of use, yet works best when coupled to either a topical antibiotic or a retinoid.

Meanwhile, European data presented at EADV 2024 elevated spironolactone’s status: in a 133-patient RCT, low-dose spironolactone outperformed doxycycline at months 4 and 6 for adult female acne, with superior quality-of-life scores.

Which eNavvi Compounds Map to Those Rules?

Below are the turnkey formulas available through Foothills Professional Pharmacy (licensed in all 50 states, two-day shipping). Each 30 g cream is $35 for a 30-day supply, and oral generics start at $6.

1. Day-time Antimicrobial Powerhouse

Benzoyl Peroxide 10 % / Clindamycin 2 % Cream

• What it covers: Oxidative killing of C. acnes plus ribosomal inhibition.
• When to choose it: Moderate inflammatory papules where you still want a separate retinoid at night.

2. Night-time Duals That Check Every Box

Clindamycin 2 % / Tretinoin (0.025 %, 0.05 %, 0.1 %) Creams

• Combines antimicrobial cover with comedolysis and epidermal remodeling.
• Three tretinoin strengths let you titrate irritation vs efficacy

3. Barrier-Friendly Retinoid Hybrids

Tretinoin (0.025–0.1 %) / Niacinamide 2 % Creams

• Niacinamide calms retinoid-induced erythema and restores ceramide synthesis within four weeks.
• Ideal for reactive or rosacea-prone skin where plain tretinoin is a hard sell.

4. Multifactorial Blend for PIH-Prone Skin

Tretinoin / Niacinamide 2 % / Azelaic Acid 8 % / Sodium Hyaluronate 0.25 %

• Adds tyrosinase inhibition and further anti-inflammatory action while hyaluronate cushions barrier disruption.
• Reach for this in Fitzpatrick IV–VI, especially if post-inflammatory hyperpigmentation shadows every lesion.

5. Topical Anti-Androgen Strategies

Spironolactone 5 % / Niacinamide 2 % Cream (± Tretinoin 0.025 %)

• Peripheral androgen blockade plus barrier support.
• Useful for jawline or truncal flares in adult women who can’t—or won’t—take oral hormonal therapy.

Systemic Staples at Mail-Order Prices

• Doxycycline 100 mg Capsules — 30 for $6 or 60 for $10.
  • Stick to 100 mg once-daily for 12–16 weeks, layer with a BPO wash or the BPO/Clinda cream above, then stop.
• Spironolactone 50 mg Tablets — 30 for $6; larger counts discounted.
  • Begin at 50 mg daily; many patients plateau nicely at 100 mg. Electrolytes are optional in healthy, normotensive women, per EADV investigators.

Practical Workflow Tips

Phenotype matching

• Oily teens: BPO/Clinda AM + higher-strength tretinoin combo PM.
• Sensitive adults: Niacinamide-rich tretinoin PM ± oral doxycycline for inflammatory nodules.

Antibiotic stewardship
Document the topical retinoid or BPO partner at initiation; many EHRs surface this for quality measures.

Tele-derm convenience
The eNavvi portal pre-populates strength, quantity, SIG, and refills. A 60-second order equals a two-day doorstep delivery with counseling inserts—no samples needed.

Hormonal acne pearls
Combining oral and topical spironolactone can address both systemic and local androgen drive without raising potassium more than monotherapy does.

Key Takeaways

• Guideline-aligned: Every cream here maps directly to 2024 AAD recommendations.
• Cost-transparent: One-price ($35) multi-agent creams sidestep prior-auth hassles.
• Fast fulfillment: 48-hour shipping to any U.S. state keeps momentum after virtual visits.

Clinical pearl: If you must resort to an oral antibiotic, set the stop date in the eNavvi order so pharmacy and patient both know when to taper off.

Disclosure & Dating: Pricing supplied by eNavvi, June 24 2025.

What is eNavvi and why should physicians care?

Imagine prescribing in under a minute, with instant cash-price comparisons and no phone calls to the pharmacy. eNavvi is a browser-based digital prescription pad created by physicians, for physicians. It replaces paper pads and clunky EMR modules with a streamlined dashboard that transmits HIPAA-compliant digital prescriptions directly to 35,000+ U.S. pharmacies. enavvi.com

Key advantages

• Zero cost – unlimited digital prescriptions every month are free under the ad-supported plan. enavvi.com
• Price transparency – Real-time cash pricing lets you pick the most affordable option. formulary.enavvi.com
• Anytime, anywhere access – Works on any device—EMR plug-in. enavvi.com

How does eNavvi work in a typical clinical encounter?

Search the drug by generic or brand name.

Compare prices across local pharmacies or mail-order partners in seconds.

Select the pharmacy that fits your patient’s budget.

E-sign & send the script—eNavvi routes it and logs confirmation.

Time-saver: Physicians report cutting pharmacy call-backs by 30-45 minutes per clinic day. enavvi.com

Is eNavvi safe and compliant?

eNavvi is HIPAA-certified, employs Vanta-verified encryption. enavvi.com

How do I start using eNavvi?

Create an account with NPI verification—it takes about 3 minutes.

Receive unlimited free Digital Rx credits each month

Bookmark the dashboard so you can launch it alongside your EMR or telehealth platform.

Invite your colleagues.

Quick benefits recap

• Cuts administrative overhead
• Boosts medication adherence via lower out-of-pocket costs
• Fits telehealth, urgent care, concierge, and direct-primary-care workflows
• Free to start—no credit card required

What Is Keratosis Pilaris?

Keratosis Pilaris (KP) is a benign but often cosmetically distressing skin condition characterized by rough, follicular papules, most commonly found on the upper arms, thighs, cheeks, and buttocks. The disorder stems from abnormal keratinization of hair follicles, resulting in the formation of small plugs that block follicular openings.

While not medically dangerous, KP can significantly affect quality of life, particularly in adolescents and young adults. Topical therapy remains the mainstay of treatment, and compounded options like those available on eNavvi can provide tailored, multi-mechanism therapy to maximize clinical response.

Pathophysiology: What’s Really Going On?

• Follicular hyperkeratinization: Overproduction of keratin traps hair shafts and leads to comedone-like plugs.

• Barrier dysfunction: KP often coexists with xerosis and atopic skin conditions.

• Inflammation: Chronic plugging can trigger perifollicular inflammation and erythema.

• Secondary pigment changes or scarring may occur in darker skin tones or with repeated trauma.

Who Gets Keratosis Pilaris?

• Children and Adolescents: Most common age of onset; may improve with age

• Atopic Individuals: Strong correlation with eczema, asthma, or allergic rhinitis

• Patients with Dry Skin: Worse in cold, dry climates

• Genetic Predisposition: Often autosomal dominant in inheritance

Clinical Features

• Rough “chicken skin” texture

• Sandpaper-like papules on extensor surfaces

• Red or brown hyperpigmentation (especially in Fitzpatrick III–VI)

• May be asymptomatic or pruritic

Treatment: Why Compounding?

Standard treatments include keratolytics (lactic acid, salicylic acid), retinoids, and emollients, but many over-the-counter options are underpowered, especially for inflammatory or resistant KP.

Compounded topicals provide:

• Higher concentration actives than OTC

• Combination therapies in a single application

• Formulations designed for patient tolerability

• Cost-effective options, with fast nationwide delivery through eNavvi

eNavvi’s Compounded Formula for Keratosis Pilaris

Diclofenac Sodium / Tacrolimus / Tretinoin / Ammonium Lactate

2% / 0.05% / 0.025% / 12%

Cream – 30 GMS – $45.00 / 30 Days – 2-Day Shipping Nationwide

When to Use This Formula

• Inflammatory KP with erythema and chronicity

• Refractory KP unresponsive to OTC urea/lactic acid

• Sensitive or atopic skin (tacrolimus offers a steroid-sparing option)

• Hyperkeratotic and pigmented lesions needing keratolytic + retinoid synergy

Mechanism Breakdown:

• Ammonium Lactate: Lactic acid derivative with keratolytic action. Softens keratin plugs and smooths skin texture.

• Tretinoin: Retinoid that increases cell turnover. Helps prevent follicular plugging.

• Diclofenac Sodium: NSAID and COX-inhibitor. Reduces perifollicular inflammation.

• Tacrolimus: Calcineurin inhibitor. Modulates immune response in inflammatory KP, especially useful for atopic skin.

Side Effects & Monitoring

• Tretinoin: Can cause irritation and peeling. Recommend starting every other night; combine with moisturizer and use sunscreen.

• Ammonium Lactate: May cause burning on broken skin. Avoid use on abraded or sensitive areas.

• Tacrolimus: May cause transient burning or stinging. Educate patients that this usually resolves with continued use.

• Diclofenac: May cause photosensitivity and mild dryness. Counsel on daily sun protection.

Clinical Tips

• Start low, go slow: Use every other night, increasing to nightly as tolerated.

• Combine with emollients: Apply a bland moisturizer in the morning.

• Expect improvement in 4–6 weeks: Complete clearance may take 8–12 weeks.

• Maintenance: Consider reducing frequency or switching to lactic acid monotherapy once improved.

Why eNavvi?

• Formulations Built for Function: High-potency actives with excellent base tolerability

• Affordable Pricing: $45 for a 30-day supply

• Rapid Fulfillment: 2-day delivery, all 50 states

• Provider-Ready Templates: Save time with pre-set prescriptions

• Clinical Flexibility: Adjust concentrations based on patient need

Conclusion

Keratosis pilaris can be more than a cosmetic nuisance—it often coexists with underlying inflammation, barrier dysfunction, and emotional distress. eNavvi’s compounded formula combining keratolytics, anti-inflammatories, and retinoids offers physicians a comprehensive and effective option, especially in treatment-resistant or atopic cases.

Tailored, potent, and accessible: compounded therapy represents the future of KP care.

What Is Eczema?

Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by episodic flares of pruritus, erythema, scaling, and lichenification. It is part of the atopic triad (along with asthma and allergic rhinitis) and reflects a complex interplay between genetic, immunologic, and environmental factors. Eczema is not a single disease but a spectrum of inflammatory skin conditions that require individualized treatment strategies.

Pathophysiology: The Underlying Immune Dysfunction

Eczema arises from a combination of epidermal barrier dysfunction and immune dysregulation. Key physiological features include:

• Filaggrin gene mutations, leading to a compromised skin barrier and increased transepidermal water loss
• Th2-skewed immune response, with elevated IL-4, IL-13, and IgE levels
• Colonization with Staphylococcus aureus, often contributing to inflammation and secondary infection
• Heightened mast cell activity, promoting pruritus and dermal reactivity

This pathophysiology supports a dual treatment approach: barrier repair and inflammation modulation, often in combination with antimicrobial or immunosuppressive strategies.

Who Gets Eczema?

• Children: Onset before age 5 is common; many outgrow symptoms but may develop other atopic disorders
• Adults: Adult-onset eczema or persistent childhood eczema can be more severe and treatment-resistant
• At-risk Populations: Individuals with a personal or family history of atopic diseases, or those living in urban or cold climates, have higher prevalence

Clinical Features

Common Symptoms:

• Intense itching
• Red, scaly patches (flexural areas in children; face, neck, or hands in adults)
• Xerosis (dry skin), cracking, and oozing
• Chronic lesions may become lichenified

When to Refer:

• Dermatologists: For moderate-to-severe disease, treatment failures, or use of systemic agents
• Allergists/Immunologists: When eczema is associated with food allergies, asthma, or requires biologic therapy
• Primary Care/Family Medicine: Initial diagnosis and mild disease management

Topical Treatment Options and Compounding Strategies

1. Atopic Eczema with Secondary Infection

eNavvi Compound: Betamethasone Valerate 0.1% / Mupirocin 2% Cream or Ointment
Mechanism:

• Betamethasone Valerate: Medium-potency corticosteroid; reduces inflammation and pruritus
• Mupirocin: Topical antibiotic targeting S. aureus colonization
  Use Case:
• Ideal for weeping, infected, or impetiginized lesions
• Choose cream for acute, moist lesions; ointment for dry or lichenified areas
  Cautions:
• Limit long-term use of topical steroids to avoid atrophy
• Monitor for bacterial resistance with prolonged mupirocin use

Available at:

• Foothills Professional Pharmacy – $35.00 / 30 Days – 2 Day Nationwide Shipping

2. Scalp Eczema / Seborrheic Dermatitis

eNavvi Compound: Clobetasol Propionate 0.055% Oil Suspension
Mechanism:

• Super-potent corticosteroid; anti-inflammatory and antiproliferative
• Oil base facilitates penetration through hair and sebaceous glands
  Use Case:
• Recalcitrant scalp eczema, seborrheic dermatitis, or psoriasiform flares
  Cautions:
• Limit to short-term use (2–4 weeks) due to risk of local and systemic corticosteroid side effects
• Avoid in infants and on thin skin areas

Available at:

• Foothills Professional Pharmacy – $35.00 / 30 Days – 2 Day Nationwide Shipping

3. Scalp Eczema with Steroid Sensitivity or Long-Term Management

eNavvi Compound: Tacrolimus 0.12% Solution
Mechanism:

• Calcineurin inhibitor; inhibits T-cell activation without skin thinning
  Use Case:
• Steroid-sparing maintenance for scalp and facial eczema
• Preferred in sensitive skin areas like the eyelids, neck, or intertriginous zones
  Cautions:
• Transient burning or stinging upon application
• Black box warning for potential cancer risk (based on animal studies); long-term human risk unproven

Available at:

• Foothills Professional Pharmacy – $35.00 / 30 Days – 2 Day Nationwide Shipping

Choosing the Right Topical Based on Clinical Presentation

PresentationRecommended CompoundRationaleInfected, crusted lesionsBetamethasone/MupirocinCombines anti-inflammatory and antimicrobial actionThick scalp plaquesClobetasol OilDeep follicular penetration for stubborn lesionsSteroid-sensitive skin or long-term useTacrolimus SolutionSteroid-sparing, no skin thinningAcute flare on face or flexuresBetamethasone/Mupirocin (short-term)Control inflammation, prevent bacterial superinfection

Conclusion

Eczema management requires a personalized approach based on disease severity, location, comorbidities, and response to previous treatments. Compounded topical therapies through eNavvi allow for customization, cost-efficiency, and expedited delivery, giving clinicians and patients access to high-quality, pharmacist-vetted formulations. With options like betamethasone-mupirocin creams, clobetasol oils, and tacrolimus solutions, podiatrists, dermatologists, and primary care providers alike can tailor treatment to optimize outcomes for every patient.

Introduction

Warts, particularly plantar warts caused by human papillomavirus (HPV), are a frequent challenge in podiatric practice. While many resolve spontaneously, persistent or painful lesions often require medical intervention. Traditional options include cryotherapy, salicylic acid, laser ablation, and immunotherapy. However, compounded topical therapies have emerged as a customizable, effective, and well-tolerated approach—especially for recalcitrant or multiple lesions.

eNavvi’s compounding platform offers podiatrists a streamlined way to access these formulations, empowering clinicians to tailor treatment based on lesion severity, patient profile, and therapeutic goals.

Why Consider Compounded Therapies?

• Customizable Concentrations: Titrate based on wart size, location, and thickness.
• Combination Formulations: Enhance efficacy by using synergistic agents.
• Improved Tolerability: Balance potency and safety for sensitive areas like plantar surfaces.
• Non-Invasive Delivery: Topical therapies offer alternatives to destructive or painful procedures.

Commonly Compounded Wart Treatments on eNavvi

Below are the most frequently used compounded wart treatments available through eNavvi, along with their mechanisms of action, indications, and cautions.

1. Cantharidin 0.7% (± Salicylic Acid 30%)

• Mechanism: Vesicant derived from blister beetle extract; induces intraepidermal blistering and local immune response.
• Indication: Non-painful application for pediatric or needle-phobic patients. Often used on thick plantar warts.
• Use: Applied in-office and occluded for several hours before removal.
• Side Effects: Blistering, pain, erythema, and potential secondary infection.
• Precautions: Avoid mucosal surfaces and use with care in diabetic patients or those with peripheral neuropathy.

2. Salicylic Acid (10–40%) in Lactic Acid or Occlusive Base

• Mechanism: Keratolytic agent that softens and exfoliates the stratum corneum, facilitating viral clearance.
• Indication: First-line for smaller, superficial lesions; safe for at-home use under guidance.
• Use: Daily application with or without occlusion.
• Side Effects: Local irritation, maceration, desquamation.
• Precautions: Limit use on infected or highly macerated skin. Higher strengths (>30%) best reserved for in-office protocols.

3. Imiquimod 5% Cream

• Mechanism: Toll-like receptor 7 agonist; stimulates local cytokine release (IFN-α, IL-12) to boost immune-mediated wart clearance.
• Indication: Recalcitrant, multiple, or mosaic warts; particularly helpful for immunocompetent patients.
• Use: Typically applied 3x weekly with occlusion; review response at 4–8 weeks.
• Side Effects: Erythema, pruritus, erosion, flu-like symptoms in rare cases.
• Precautions: Avoid overuse to minimize inflammatory response; not ideal for immunocompromised individuals.

4. 5-Fluorouracil (5-FU) 5% with Salicylic Acid 17–30%

• Mechanism: Antimetabolite that disrupts viral DNA synthesis; synergistic with salicylic acid’s keratolytic action.
• Indication: Thick or treatment-resistant warts, especially in older adolescents or adults.
• Use: Applied daily under occlusion, typically at night for 6–12 weeks.
• Side Effects: Irritation, erosion, photosensitivity.
• Precautions: Contraindicated in pregnancy; avoid sun exposure on treated areas.

5. Cimetidine (Oral or Topical, Off-label)

• Mechanism: H2 receptor antagonist with immunomodulatory effects; enhances T-cell mediated response.
• Indication: Multiple warts, especially in pediatric or immunologically naive patients.
• Use: Topical versions are compounded at 5–10%; oral regimens can be considered adjunctively.
• Side Effects: Minimal topically; oral use may cause headaches or GI upset.
• Precautions: Topical use is generally safe; limited robust data on efficacy.

eNavvi’s Advantage for Podiatrists

eNavvi’s digital compounding pad streamlines access to high-quality, physician-curated wart treatments. Each compound is:

• Delivered Nationwide with transparent cash pricing.
• Integrated with podiatry-specific templates to reduce prescribing friction.

You can select from our prebuilt wart treatment protocols or customize formulations based on lesion size, location, and patient tolerance.

Conclusion

Compounded topical wart treatments offer podiatrists a flexible, evidence-based approach to managing verrucae, particularly for refractory or challenging cases. eNavvi’s platform enhances your ability to deliver precision therapy while minimizing procedural burden. From cantharidin and salicylic acid to advanced immunomodulators, compounded options can be tailored to your clinical goals—and your patient’s lifestyle.

Introduction

PT-141, chemically known as Bremelanotide Acetate, is a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH). It acts primarily as a melanocortin receptor agonist, targeting central nervous system pathways involved in sexual arousal and desire. Its novel mechanism of action has led to growing clinical interest, particularly in managing sexual dysfunction where traditional vasodilator agents (e.g., PDE5 inhibitors) have been insufficient or contraindicated.

Mechanism of Action

PT-141 activates melanocortin receptors MC3R and MC4R located primarily within the hypothalamus. These receptors modulate pathways associated with sexual arousal, libido, and sexual satisfaction through central nervous system signaling rather than peripheral vasodilation. Unlike PDE5 inhibitors (e.g., sildenafil), PT-141's primary therapeutic effect is centrally mediated, enhancing sexual desire independently from direct vascular mechanisms¹.

FDA Approval and Indications

PT-141 was approved by the FDA in June 2019 under the brand name Vyleesi® specifically for the treatment of:

• Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women².

The indication includes women who experience persistent low sexual desire causing marked distress or interpersonal difficulties and is not attributed to existing medical or psychiatric conditions, relationship problems, or medication side effects.

Clinical Use and Administration

Approved Administration

• Subcutaneous injection:
  The FDA-approved product, Vyleesi®, is administered via a disposable autoinjector device approximately 45 minutes before anticipated sexual activity. Patients are advised not to exceed one dose in 24 hours and a maximum of eight doses per month².

Off-label Administration

• Intranasal administration (compounded):
  Due to patient preference for non-injectable options, compounding pharmacies frequently formulate PT-141 as intranasal sprays. This method bypasses hepatic first-pass metabolism, rapidly crossing the blood-brain barrier and initiating a faster onset of action. The standard compounded intranasal concentration typically ranges from 1 mg/ml to 10 mg/ml, dosed approximately 30–60 minutes prior to anticipated sexual activity³.

Benefits of PT-141

• Centrally Mediated Libido Enhancement:
  Unlike PDE5 inhibitors that rely primarily on vascular response, PT-141 directly enhances libido by central pathways.
• Applicable Across Sexes:
  While FDA approval is specific to women, clinical and anecdotal evidence suggest efficacy in men, particularly those inadequately responsive to PDE5 inhibitors.
• Rapid Onset:
  The compounded intranasal formulation typically offers quicker onset (within 30–60 minutes), enhancing usability and spontaneity.
• Alternative for Vasculogenic ED Non-Responders:
  Useful in patients who do not respond to traditional erectile dysfunction medications due to underlying cardiovascular conditions or other contraindications⁴.

Risks and Side Effects

PT-141 has several potential adverse effects, including:

• Nausea (most common): Occurs in approximately 40% of patients; typically mild and transient.
• Flushing: Usually brief, transient, and mild to moderate in intensity.
• Headache, dizziness: Generally mild but can impact patient adherence.
• Injection site reactions: For the subcutaneous route, including redness, pain, or swelling.
• Transient hypertension: Elevated blood pressure observed in some patients, caution advised in hypertensive individuals²⁵.

Patients with uncontrolled hypertension or significant cardiovascular disease should approach treatment with caution.

Compounded Intranasal PT-141: Clinical Considerations

Formulation and Dosing

• Standard Intranasal Formulation: Typically compounded at concentrations of 1 mg/ml to 10 mg/ml.
• Dose Recommendations: Usually initiated at 1–2 sprays (approximately 0.5–2 mg per spray) per nostril, titrated based on patient response and tolerability.

Pharmacokinetics

• Rapid Absorption: Intranasal delivery bypasses the gastrointestinal tract and hepatic metabolism, enhancing rapid onset of action compared to subcutaneous or oral administration.
• Shorter Duration: Effects typically last several hours, correlating well with desired timing of sexual activity³.

Patient Counseling Points

• Timing and Spontaneity: Educate patients on the optimal timing of administration (30–60 minutes pre-activity).
• Side Effects Management: Nausea can be minimized by starting at lower doses and gradually titrating upward as tolerated.
• Safety Profile: Regularly monitor blood pressure in susceptible patients, especially during initial treatment phases.

Summary and Clinical Pearls

PT-141 (Bremelanotide Acetate) offers a unique therapeutic option for managing sexual dysfunction through central nervous system modulation of libido pathways. FDA-approved for premenopausal women with HSDD, it also demonstrates off-label efficacy in male populations and those resistant to traditional vasodilators. Compounded intranasal formulations further enhance patient adherence, convenience, and rapidity of onset.

Introduction

Androgenetic alopecia (male pattern baldness) is the most common form of hair loss in men, affecting approximately 30–50% of men by age 50. Compounded topical creams enable precise local delivery of active agents, combination therapies, and reduced systemic exposure—key advantages in long-term management of hair loss.

Pathophysiology & Therapeutic Targets

Follicular miniaturization in androgenetic alopecia is driven by dihydrotestosterone (DHT). Effective topical therapies aim to:

• Inhibit DHT at the follicle (5α-reductase blockers)
• Promote vasodilation to prolong the anagen phase (minoxidil)
• Optimize local drug exposure while minimizing systemic levels

Compounded Formulations

1. Topical Finasteride (0.1–0.5%)

• Mechanism: Selective inhibition of type II 5α-reductase reduces DHT within the follicle.
• Clinical Data: A 0.25–0.5% finasteride spray produced significant increases in terminal hair count versus placebo, matching the efficacy of oral finasteride with minimal systemic DHT suppression.
• Dosing: Apply once daily to areas of thinning.

2. Topical Minoxidil (2–10%)

• Mechanism: Potassium-channel opener that enhances perifollicular blood flow and prolongs anagen.
• Evidence: A 5% solution outperforms 2% and placebo in non-vellus hair count; higher concentrations up to 10% have been explored in compounding settings.
• Dosing: Typically applied twice daily.

3. Topical Dutasteride (0.1–0.5%)

• Mechanism: Dual inhibition of 5α-reductase types I and II, offering more potent DHT reduction.
• Data: Topical dutasteride has demonstrated hair-regrowth comparable or superior to finasteride with negligible systemic exposure in early trials.
• Dosing: Often applied once daily, with titration based on response.

4. Combination Formulations

• Rationale: Synergistic targeting of DHT inhibition and vasodilation.
• Clinical Insight: A cream combining 5% minoxidil with 0.25% finasteride yielded faster and greater improvements in hair density compared to minoxidil alone (86.7% vs 69.1% efficacy at 24 weeks).

Vehicle Considerations & Stability

• Bases: Ointments (e.g., petrolatum), gels (e.g., pluronic lecithin organogel), and emulsions affect drug release and scalp retention.
• Stability: Nonaqueous vehicles preserve the integrity of finasteride and dutasteride; maintaining pH between 4.5 and 7.5 optimizes stability and minimizes irritation.
• Patient Tolerance: Lightweight gels enhance compliance in oily scalps; ointments may suit dry or sensitive skin types.

Compounding Best Practices

Use USP-grade active pharmaceutical ingredients to ensure purity.

Assign beyond-use dates based on vehicle compatibility (typically 30–60 days for nonaqueous preparations).

Adjust pH with appropriate buffers for skin compatibility.

Dispense in airless or amber containers to protect photolabile compounds.

Verify uniformity and potency through in-process assays.

eNavvi’s Online Compounding Platform

• Custom Prescriptions: Access vetted templates or fully tailor finasteride, minoxidil, dutasteride, or combination creams.
• Transparent Pricing: View cash prices upfront with no hidden fees.
• Nationwide Delivery: Accredited compounding pharmacies ship to all 50 states within two business days.

Introduction

Anal fissures and hemorrhoids are among the most common anorectal disorders, affecting up to 50% of adults by age 50 and causing significant discomfort, pain, and bleeding.¹ Tailored topical therapies delivered via compounded creams can optimize drug concentrations, combine synergistic agents, and improve patient adherence. This blog provides high-level clinical insights into the most commonly compounded formulations for anal fissures and hemorrhoids, along with practical guidance on vehicle selection, stability, and eNavvi’s streamlined compounding services.

Pathophysiology & Therapeutic Targets

• Anal fissures are linear tears in the anoderm caused by trauma (e.g., hard stools), leading to internal sphincter hypertonia, local ischemia, and pain.
• Hemorrhoids arise from dilated vascular cushions in the anal canal due to increased venous pressure, resulting in pruritus, pain, and bleeding.

Topical treatments aim to:

Reduce sphincter pressure (improve blood flow and pain control).

Promote mucosal healing (protective agents and growth factors).

Alleviate inflammation and pruritus.

Compounded Formulations for Anal Fissures

1. Glyceryl Trinitrate (Nitroglycerin) 0.2–0.4% Cream

• Mechanism: Nitric oxide donor that relaxes internal anal sphincter, enhancing perfusion.
• Dosing: Apply a pea-sized amount twice daily.
• Evidence: A randomized dose-finding study demonstrated improved healing rates in chronic fissures with 0.2–0.4% NTG versus placebo

2. Topical Calcium Channel Blockers

• Nifedipine 0.5% Cream
  • Superior to 0.2% NTG for pain relief, healing rate, and fewer side effects
• Diltiazem 2% Ointment
  • Effective in reducing sphincter tone and promoting fissure healing, often used when nifedipine is contraindicated.

3. Sucralfate 7% (± Metronidazole 1%) Cream

• Mechanism: Forms a protective polyanion gel that enhances mucus production and growth factor activity, promoting epithelial repair.
• Combination Therapy: Adding metronidazole 1% may offer antimicrobial support without compromising healing; studies show efficacy comparable to diltiazem 2%

Compounded Formulations for Hemorrhoids

1. Lidocaine 2–5% & Hydrocortisone 2% Cream

• Lidocaine (2–5%) provides rapid analgesia via sodium channel blockade; 5% formulations (e.g., RectiCare®) can be applied up to six times daily.
• Hydrocortisone 2% reduces inflammation, pruritus, and edema.
• Dosing: Apply a thin film 2–3 times daily to the perianal area; rectal cream versions may be inserted twice daily.

2. Phenylephrine 0.25–1% Cream

• Mechanism: α-adrenergic agonist that vasoconstricts hemorrhoidal vessels, reducing edema and discomfort.
• Use: Typically compounded for precise titration when OTC strengths are insufficient.

Vehicle Selection & Stability

• Bases: Nonaqueous vehicles (e.g., white petrolatum, pluronic lecithin organogel) enhance adhesion and residence time, reducing leakage.
• Stability: Studies recommend petrolatum bases to maintain potency of NTG, nifedipine, and hydrocortisone preparations.

Compounding Best Practices

Quality Control: Use USP-grade active ingredients; conduct batch testing.

pH Adjustment: Maintain pH 4.5–7.0 for skin compatibility.

Preservatives: Incorporate as needed for water-containing formulations.

Packaging: Utilize airless dispensers or light-protective tubes for photolabile agents.

eNavvi’s Online Compounding Platform

• Digital Prescription Pad: Select from clinician-vetted templates or customize formulations.
• Transparent Pricing: Cash prices displayed upfront, with no hidden fees.
• Fulfillment: Partner pharmacies accredited for compounding deliver nationwide in two days to all 50 states